- Home
- WOLF vs AVTX Comparison
WOLF vs AVTX Comparison
Compare WOLF & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOLF | AVTX |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 982.5M |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | WOLF | AVTX |
|---|---|---|
| Price | $31.55 | $19.51 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $14.33 | ★ $40.57 |
| AVG Volume (30 Days) | ★ 4.0M | 789.3K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 19.00 | ★ 2312.27 |
| 52 Week Low | $1.16 | $8.41 |
| 52 Week High | $80.82 | $24.27 |
Technical Indicators
Market Signals| Indicator | WOLF | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 55.81 |
| Support Level | $15.86 | $17.40 |
| Resistance Level | $60.25 | $20.68 |
| Average True Range (ATR) | 2.64 | 1.16 |
| MACD | 1.49 | 0.01 |
| Stochastic Oscillator | 82.85 | 78.22 |
Price Performance
Historical ComparisonAbout WOLF Wolfspeed Inc.
Wolfspeed Inc develops and manufactures semiconductor technologies based on silicon carbide (SiC) for power electronics applications. Its product portfolio includes SiC MOSFETs, Schottky diodes, and power modules used in power electronics applications. The company also provides reference designs, evaluation kits, and gate driver boards to support the development and integration of its SiC products across industries such as electric vehicles, renewable energy, and industrial systems.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.